Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 28% Jump Looks Justified

Simply Wall StFeb 14 18:37 ET

Insiders Of CStone Pharmaceuticals Reap Rewards After Their Investment Jumps Another CN¥13m

Simply Wall StFeb 11 18:52 ET

CStone Pharmaceuticals' Lung Cancer Drug Included in ESMO Living Guideline

MT NewswiresFeb 10 01:44 ET

CSTONE PHARMA-B (02616.HK): Suglituzumab (Zhejie Mei) has been recommended as a first-line treatment in the ESMO guidelines for dual indications in non-small cell lung cancer.

On February 10, GELONGHUI reported that CSTONE PHARMA-B (02616.HK) announced that its major product Suglizumab (Zhaojimei) has been included in the "ESMO Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer (NSCLC) Living Guideline" ("ESMO Guideline") by the European Society for Medical Oncology, while also becoming a part of squamous and non-squamous non-small-cell lung cancer.

Gelonghui FinanceFeb 9 23:04 ET

Express News | CStone Pharmaceuticals - Announces Inclusion of Sugemalimab (Cejemly®) as First-Line Combination Therapy for Nsclc

ReutersFeb 9 23:01 ET

Goldman Sachs has included CSTONE PHARMA-B (02616) CS5001 in the list of anticipated BD collaborations for 2025.

Among many innovative projects, CSTONE PHARMA-B (02616) underlines the innovative antibody-drug conjugate CS5001 (ROR1 ADC) which has received significant attention.

Zhitong FinanceFeb 9 19:29 ET